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ABSTRACT 
Objective: The purpose of this study is to evaluate the demographics, disease profile and 
treatment outcome of patients treated at Groote Schuur Hospital in Cape Town for 
Plasmablastic Lymphoma over a 5 year period extending from 2004 to 2009.  
Background: Plasmablastic lymphoma (PBL) is a highly aggressive rare subtype of Diffuse 
Large B-Cell Lymphoma first described in 1997. The diagnosis of PBL remains a challenge 
despite advances in diagnostic tools. There is no established standard of care, although CHOP 
chemotherapy is an accepted choice of treatment. The prognosis is poor even with more 
intense chemotherapy regimens. 
Methods: Medical records of 28 patients treated for PBL between January 2004 and 
December 2009 were reviewed. Factors evaluated for the impact on overall survival (OS) 
included stage, IPI, CD4 count, chemotherapy alone vs. chemotherapy and radiotherapy, 
extranodal status and gender. Kaplan –Meier methods were used to compare patient 
outcomes including the 1 and 3 year survival proportions respectively. 
 Results: There were 25 HIV positive patients. The median age at presentation for the HIV 
positive group was 35 years (30-57) with a slight female predominance. Distribution of 
population by race was 80% blacks, 16% mixed race and 4% whites. CHOP chemotherapy 
was used as the primary treatment in our institution and patients with early stage disease 
received radiotherapy after chemotherapy. The objective overall response rate was 68% for 
HIV positive patients with a median OS of 52 weeks. Factors associated with good survival 
outcome were early stage disease, combination of chemotherapy with radiotherapy and low 
IPI score. The one and three year OS were 45% and 39% respectively with a relapse rate on 
average of 17%. 
Conclusion: To date the survival outcome for PBL remains very poor regardless of 
intervention. In this study the primary treatment was CHOP chemotherapy which was 
combined with radiotherapy when indicated. The survival outcomes in this study are 
comparable to previously published studies but with a superior proportion of surviving 
patients 5 years post treatment. Good prognosis is associated with early stage disease and 
treatment with combination of chemotherapy and radiotherapy.  
Key Words: Plasmablastic Lymphoma, HIV, overall survival, CHOP chemotherapy, PBL, 
prognostic factors, IPI (International Prognostic Index) 
8 
MMED STUDY PROTOCOL 
Tittle of Project 
Retrospective Study of Patients Treated for plasmablastic lymphoma(PBL) at Groote Schuur 
Hospital between 2004 and 2009 
Research Question 
What are the treatment outcomes, disease profiles and demographics of a group of patients 
treated for plasmablastic lymphoma in Groote Schuur Hospital over a five year period 
ranging from 2004 to 2009?  
Purpose of Study 
The purpose of this study is to retrospectively evaluate the treatment outcomes, disease 
profiles and demographics of patients with plasmablastic lymphoma. 
Patient Population 
This study included all patients over the age of 18 with a confirmed histological diagnosis of 
plasmablastic lymphoma treated at Groote Schuur Hospital between 2004 and 2009. 
Background 
Plasmablastic lymphoma is a highly aggressive, rare subtype of Diffuse Large B-Cell 
Lymphoma. This condition was first described by Delecluse et al in 19971. It is widely 
described in HIV positive patients and accounts for 2.6% of all HIV related Non-Hodgkin 
lymphomas 2. This tumour mostly occurs in the oral cavity. It is most common in the middle 
aged group ranging from 35-55 years3 but it has been reported in the paediatric population. 
There is not a lot of data available in the literature. A few cases have been reported in HIV 
negative patients with most of them having immunosuppressive conditions which include 
transplant patients on immunosuppressive drugs or chronic steroid use, Crohn’s disease and 
also seen in immunocompetent patients4-9. Most reported cases are associated with Epstein-
Barr virus (EBV) and the role of Human Herpes Virus 8(HHV8) is not yet clear10, 11.   
The incidence has increased following the introduction of HAART.  These lymphomas are 
thought to be frequently resistant to therapy with a poor prognosis, high relapse rates and 
9 
death occurring 1 to 24 months after diagnosis. There are currently no clear and validated 
treatment guidelines.  CHOP chemotherapy is widely accepted as first line of treatment and 
variable treatment options are available for relapsed disease 12. 
This study will be among the larger cohorts done on this topic and the information obtained 
may be useful in the management of this rare malignancy locally and worldwide. 
Objective 
The primary objective of this review is to evaluate the survival outcomes of plasmablastic 





 The other objectives will be to evaluate the influence of: 
 Tumour related factors including disease site, stage, B-symptoms, performance status,
lactate dehydrogenase  and International Prognostic score
 HIV related factors including whether on HAART at lymphoma diagnosis, CD4 count
at diagnosis, opportunistic infections or presence of any other malignancies.
Methods and Data Collection 
Folders for patients treated for PBL between 2004 and 2009 were retrospectively reviewed. 
The list for these patients was obtained from the Groote Schuur Hospital Radiation Oncology 
Department.  Ethics approval was obtained from the Health and Research Ethics Committee 
of the University of Cape Town and permission from the Clinical Director of Groote Schuur 
Hospital was obtained before commencement of the study.  A literature review was 
performed using PubMed, Google, available journals and text books. 
All folders reviewed included only patients over the age of 18 years with a confirmed 
histological diagnosis of PBL. The data extracted was recorded into customised data sheets 
and transferred into an excel spreadsheet.  
10 
The data collected included age at diagnosis, date of presentation, gender, ethnic group, site 
of disease, stage of disease, ECOG performance status, Lactate Dehydrogenase (LDH) and 
the International Prognostic Index (IPI). The IPI was calculated by incorporating the 
following factors; age >60 years, serum Lactate dehydrogenase (LDH) levels >1x normal, 
ECOG performance status of 2-4, stage III or IV and >1 extranodal site involvement. The 
presence of B-symptoms which included weight loss of >10% in the last 6 months, 
unexplained fever or night sweats was noted. 
In addition to the above, HIV status, CD4 count and viral load when available were included 
in the data sheet as well as the presence of any infections like pulmonary tuberculosis (PTB) 
and varicella zoster, and other malignancies like Kaposi sarcoma. Time on HAART at 
diagnosis was also recorded  
The treatment approach was documented including the chemotherapy regimen used, number 
of cycles completed and radiotherapy doses for those patients who received radiotherapy. 
Responses to treatment were recorded as complete response (CR), partial response (PR) and 
progressive disease (PD). For patients who achieved a complete response and relapsed, the 
time to relapse, site of relapse and the treatment offered for the relapse was documented. 
At last follow up, the patients’ status was recorded as either alive with disease, alive without 
disease or dead, and if recorded as dead it was noted whether they died from lymphoma or 
other causes. 
Statistical analysis was performed using GraphPad Prism version 6 for Windows. Overall 
Survival (OS) was calculated from time of registration to time of death due to lymphoma or 
any other cause or date last seen for patients lost to follow up. Progression Free Survival 
(PFS) was calculated from time of registration to time of first progression on primary 
treatment, death or date last seen for those patients lost to follow up. Survival curves were 
generated using the Kaplan-Meier method and compared using the log rank test. A p value of 
<0.05 was considered statistically significant. 
11 
Dr. Sebathu P Chiyapo 
Division of Radiation Oncology 
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Objectives of literature review 
The objective of this literature review is to provide the reader with background information 
on the topic in order to justify this study and present research done by other authors in the 
field. This will allow data comparison, identify new evidence in the literature and recognise 
areas that require further research. 
Literature Search strategy 
For this study, articles relating to plasmablastic lymphoma were searched for using the 
following search engines; PubMed, Google, Google scholar, read by QXMD app, text books 
and journal articles. These studies were published from 1997 after the first article describing 
plasmablastic lymphoma was published. Although plasmablastic lymphoma was the main 
search term used, other HIV related lymphomas and B-cell lymphomas were also included in 
the search as these conditions are clinically similar. Only publications in the English language 
were included in this review. 
In the last decade several case reports have been published exploring the pathogenesis, 
clinical behaviour, treatment options and outcomes, influence of HAART and prognostication 
of plasmablastic lymphoma. These are mostly case reports and single institution retrospective 
studies. There are no published meta-analyses or phase III studies, which in clinical practice 
are believed to confer a higher level of evidence with regard to plasmablastic lymphoma.   
Interpretation of literature 
In order to understand and discuss the results of the current study, a detailed review of the 
available literature was performed and discussed. This review will summarise plasmablastic 






d) Pathological features 
e) Clinical presentation  




a) Background information 
Plasmablastic lymphoma is a highly aggressive, rare subtype of diffuse large B-cell 
lymphoma (DLBCL). This condition was first described by Delecluse and colleagues in 
1997. The subjects described by Delecluse all presented with oral cavity involvement and the 
majority were HIV positive 
1
. Recently, the literature has reported a more heterogeneous 
involvement by site 
2, 3
. 
Although plasmablastic lymphomas were initially reported in HIV positive adults, emerging 
literature describes this malignancy in immunocompetent individuals with no known medical 
history 
4, 5
. However, some HIV negative patients reported on were immunosuppressed due to 
drugs like chronic steroids for autoimmune conditions, chronic viral infection 
3
 or in the post-
transplant setting 
2, 6
. Plasmablastic lymphoma has been reported in the paediatric population 
both in the setting of HIV infection and in immunocompetent children 
7, 8
.  
Over the last decade and a half, several reports have emerged describing plasmablastic 
lymphoma. These have been small reviews including single institutional case studies and 
retrospective studies. The classification of plasmablastic lymphoma has changed quite 
significantly in the last decade and a half. In 2001, the WHO classified plasmablastic 
lymphoma as a lymphoma of the oral cavity occurring more specifically in people who are 
HIV positive. This nomenclature was chosen due to the predominant occurrence in the oral 
cavity. In 2008, the WHO classified plasmablastic lymphoma as a separate category under 
aggressive B-cell lymphomas and the nomenclature is no longer restricted to the oral cavity 





This malignancy presents a dilemma in that the pathogenesis, clinical presentation and 
treatment outcomes are poorly understood. There is no established standard of care therapy 
for primary or relapsed disease. Despite the treatment approach used, response rates can be 
high but relapse rates are also high and death can occur within one month to two years after 
diagnosis 
10
. In the setting of HIV infection the introduction of highly active anti-retroviral 
therapy (HAART) has led to improved overall survival rates and response rates in patients 
with AIDS related lymphomas but studies have shown conflicting results since the incidence 
of AIDS related lymphomas has changed with the introduction of HAART 
11-14
. 
This malignancy is believed to carry a poor prognosis; however several studies have failed to 
establish prognostic factors associated with plasmablastic lymphoma. Several studies with 
conflicting results have been published on prognostication of plasmablastic lymphoma 
4, 10, 15
. 
The emergence of aggressive AIDS related lymphomas like plasmablastic lymphoma, 
Burkitt’s lymphoma and primary effusion lymphoma pose a health challenge in the Sub-
Saharan region where there are limited resources allocated to health care.  
In South Africa there is a paucity of data available on AIDS-related malignancies. With the 
high incidence of HIV in this setting as evidenced by the Midyear Population Estimates 2011 
report by Statistics South Africa 
16
, an increased incidence of AIDS related lymphomas 




b)  Epidemiology 
Plasmablastic lymphoma is a rare malignancy. The true incidence is unknown but it is 
estimated to make up to 2.6% of all HIV related Non-Hodgkin lymphomas 
17
. The majority 
of patients are in the 35-55 age population group and the incidence is higher in males 
18, 19
.  
The majority of cases are associated with HIV infection. The demographics of this disease 
are unclear but it has been reported in various populations from across different continents 
and countries 
11, 20-22
. In a study by Abayomi et al, they noted an increase in the incidence of 
AIDS related lymphomas in the Western Cape in South Africa over an eight year period and 
the emergence of new entities like plasmablastic lymphoma. They also noted that the roll out 
of HAART in 2004 did not appear to have had any impact on the incidence of AIDS related 





Wiggill and her colleagues in a study performed in Johannesburg, South Africa demonstrated 
an increase in the incidence of lymphoproliferative malignancies in the HIV positive 
population from 44.3% between 2004 and 2006 to 62% between 2006 to 2009 
23
. The same 
study also showed a decrease in the age at presentation from a median age of 47 in the HIV 
negative to 36 in the HIV positive and the male to female ratio. Several other studies have 





The available pathological, immunohistochemical, molecular and genetic data suggests that 
plasmablastic lymphoma arises from post-germinal centre, terminally differentiated, activated 
B-cells in transition from immunoblasts to plasma cells 
26
. 
Epstein - Barr virus (EBV) has been found to be associated with AIDS related lymphomas 
and is thought to play a key role in its pathogenesis. In one series there was a 70% association 
between plasmablastic lymphoma and EBV 
10, 27-29
. EBV is a gamma herpes virus implicated 
in the aetiology of malignancies like Hodgkin’s lymphoma, Burkitt’s lymphoma, 
nasopharyngeal carcinoma and HIV-related lymphomas.  The role played by EBV in the 
pathogenesis of plasmablastic lymphoma is being explored. Carbone and colleagues 
postulated that EBV encodes a series of products interacting with a wide variety of 
antiapoptotic molecules, cytokines and signal transducers thereby promoting EBV infection, 
cell immortalization and transformation to malignant cells and also has the capacity to induce 
unlimited proliferation of B-lymphocytes by in vitro transformation 
27, 30
. 
In a study by Qing and colleagues, a case of plasmablastic lymphoma occurring as a result of 
transformation from plasmacytoma was reported 
31
. This was reported by others who 
demonstrated the immunophenotypic similarities between plasmablastic lymphomas and 
plasma cell myelomas 
6
. These findings were however refuted by studies demonstrating 
conflicting results. Chung Che and colleagues reported more similarities with DLBCL than 
plasma cell myelomas 
32
. 
Human Herpes Virus 8 (HHV8), another member of the herpes virus family, has been 
associated with the pathogenesis of other AIDS related malignancies like Kaposi’s sarcoma 
and Castleman’s disease. It does not appear to play a role in the pathogenesis of plasmablastic 
19 
 
lymphoma, except in documented cases of plasmablastic lymphoma arising in HHV8 
associated Multicentric Castleman’s disease 
33, 34
. This type of plasmablastic lymphoma is 





Plasmablastic lymphoma is associated with rearrangements in the c-myc gene in more than 
40% of cases 
36, 37
. Valera and colleagues reported c-myc rearrangement in 50% of cases 
reviewed and noted that EBV positive patients were more likely to have the c-myc 
abnormality. Conversely, c-myc rearrangement occurred less frequently in EBV negative 
patients 
38




Other theories of pathogenesis have been postulated. Martinez and colleagues reported six 
cases of plasmablastic differentiation as a transformation from low grade B-cell lymphomas 




The pathogenesis of this malignancy is an active area of research. Understanding the 




d) Pathological features 
Plasmablastic lymphomas share morphological, pathological and immunohistochemical 
characteristics with other types of lymphomas notably diffuse large B-cell lymphoma, 
Burkitt’s lymphoma and plasma cell myelomas. Chung Che and colleagues reported more 
similarities between plasmablastic lymphoma and diffuse large B-cell lymphoma than with 
plasma cell myelomas 
32
. These results differed from the findings of Qing and colleagues 
who described a picture more similar to plasma cell myelomas than diffuse large B-cell 
lymphomas 
31
. These similarities can make the diagnosis difficult and adversely affect the 
management of plasmablastic lymphoma. 
Although Plasmablastic lymphomas are described as aggressive B-cell lymphomas they lack 





CD20 expression was found to be higher in the HIV positive group compared to the HIV 
negative group in a study by Castillo and colleagues 
4
. These malignancies express plasma 
cell markers like CD38, CD138, VS38C and MUM1 (multiple myeloma oncogene-1). 
Immunohistochemistry is essential in the diagnosis of Plasmablastic lymphoma. In the 
resource-limited Sub-Saharan setting the diagnosis of Plasmablastic lymphoma presents a 
challenge as immunohistochemistry is not always available. The newer stains used in the 
identification of Plasmablastic lymphoma like PRDM1/BLIMP1 protein and XBP1 proteins 
42
 are not cost effective in this setting. 
Kane and colleagues, working at a cancer institute in India proposed that the minimum 
immunohistochemical tests required to be able to diagnose plasmablastic lymphoma includes 
the CD20, CD138 and CD38 stains as well as a ki-67>60% and expression of EBV
43
. These 
may not be available at all laboratories in the developing world. 
FISH studies have demonstrated myc/IgH mutations which are also present in Burkitt’s 
lymphoma and found to a lesser extent in aggressive B-cell lymphomas 
38
. These genetic 
aberrations are associated with a more aggressive course and worse treatment outcome. 
 
e) Clinical presentation 
In the initial studies, plasmablastic lymphoma was reported in HIV positive patients and 
mostly described in the oral cavity 
1, 44
. This malignancy has now been found to occur in the 
HIV negative population as well. Castillo and colleagues described 76 HIV negative patients 
with plasmablastic lymphoma. They concluded that plasmablastic lymphoma in the HIV 
negative population had a striking predilection for extraoral sites and had less association 
with EBV than in the HIV positive group. Overall survival was shorter in the HIV negative 
cohort 
4
. Similar results were reported by Liu and colleagues, who also reported a higher 
incidence of women and a higher median age at presentation in the HIV negative population 
45
. At present it is unclear if the introduction of HAART has modified these factors. 
Both HIV positive and HIV negative plasmablastic lymphoma have been shown to involve 
multiple heterogeneous sites. Other sites reported include the larynx 
46
, central nervous 
system, gastrointestinal system, kidneys and skin 
2, 4, 5, 47
. Extranodal involvement occurs 
21 
 
much more frequently than nodal involvement in plasmablastic lymphoma 
10
.  It is unclear 
whether oral and extraoral plasmablastic lymphomas are the same clinical entities. 
 Hansra and colleagues reported that patients with oral involvement had a better overall 
survival than those with extraoral plasmablastic lymphoma.  This may indicate that these are 
two different clinicopathologic entities 
48
. Plasmablastic lymphoma can be the initial 
presentation in patients with previously unknown HIV status 
49
 or can present in patients 
known to be HIV positive on HAART. In patients known to be HIV positive the average 
CD4 count at presentation with lymphoma is 178 cells/mm3 and the average viral load is 
86,000 copies/mL from a study by Castillo and colleagues, B symptoms including more than 
10% weight loss, unexplained fever or night sweats has been shown to be more common in 
the HIV negative than the HIV positive population. The same study also shown LDH is 
elevated in the majority of patients at presentation particularly in those who present with 




f) Treatment and treatment response. 
Plasmablastic lymphomas are thought to be resistant to standard Non-Hodgkin’s lymphoma 
therapy with poorer prognosis and death occurring within a months after diagnosis. There is 
no established standard of care or validated treatment protocols for plasmablastic lymphoma. 
Cyclophosphamide, Oncovin (vincristine), Adriamycin (hydroxydaunorubicin) and 
Prednisone (CHOP) chemotherapy regimen and CHOP like regimens have been used 
worldwide and is accepted as first line treatment 
10
. The NCCN however recommends more 
aggressive and intense treatment approaches like CODOX/IVAC (cyclophosphamide, 
vincristine, adriamycin, methotrexate, ifosfamide, etoposide and cytarabine), dose adjusted 
EPOCH (etoposide, adriamycin, vincristine, cyclophosphamide and prednisone) and 
HyperCVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone, methotrexate and 
cytarabine) 
50
. The NCCN guidelines state that CHOP is an inadequate treatment. This is 
based on evidence from case reports only since there are no randomised clinical trials in this 
regard. 
With CHOP and CHOP like regimens high objective response rates have been achieved. 
Castillo and colleagues described complete response rates of 46% and partial response rates 
22 
 
of 31%. In the same study 72% of patient’s progressed and 57% were deceased at the time of 
publication.  The overall survival achieved in the same study was 31% at 5 years with a 
median survival of 14 months 
15
. These results were echoed by other studies 
4, 10, 51
.  Long 
term survival is a rare phenomenon in plasmablastic lymphoma. Sharma and colleagues 
report on a patient still alive eight years post treatment 
52
 which appears to be the longest 
survivor in the reviewed literature. 
With the introduction of HAART improved overall survival rates and response rates have 
been observed 
21, 53, 54
.  A few cases of spontaneous regression have been documented with 
the use of HAART only 
55, 56
. 
Bortezomib, a proteasome inhibitor effective in the management of multiple myeloma has 
been studied in patients with plasmablastic lymphoma. Bibas and colleagues used bortezomib 
alone or in combination with dexamethasone, oxaliplatin, gemcitabine, cytarabine and 
pegfilgrastin (GOVDD regimen). They reported that the results were promising but they 
failed to show any survival advantage over standard chemotherapy 
57
. 
Rituximab, an anti-CD20 monoclonal antibody, is widely used as the standard of care in 
combination with CHOP chemotherapy for Diffuse Large B-cell lymphoma. Occasionally 
there is weak expression of CD20 in some cases of Plasmablastic lymphoma 
10
 and therefore 
the use of rituximab has been suggested in this group. 
Castillo and colleagues evaluated treatment outcomes in patients receiving CHOP, CHOP-
like regimens and more intense regimens. They reported no statistical difference in the 
overall survival between the less and more intensive treatment regimens 
15, 58
. 
High dose chemotherapy and stem cell transplant is a well documented treatment for DLBCL 
at relapse, and other highly aggressive lymphomas in first remission.  Its role and 
effectiveness in the management of plasmablastic lymphoma has not been tested but some 
authors suggest that it may be a viable option for use at first remission 
36, 58, 58
. 
Radiotherapy has also been used in the treatment or in combination with chemotherapy with 
or without HAART with inconclusive results 
10, 15
. It is generally used as palliative therapy. 
23 
 
In cases of relapsed or refractory disease the data concerning further management is scanty. 
Palliative chemotherapy and radiotherapy or combinations of the two are viable treatment 
options, but due to high mortality rates there is limited data available to substantiate its use. 
 
g)  Prognosis  
A few studies have investigated possible factors influencing prognosis in plasmablastic 
lymphoma. In a study by Castillo et al early clinical stage and complete response to 
chemotherapy were associated with improved survival rates 
15
. In another study with 112 
reported cases (oral and extra oral) 66% achieved a complete response and 29% progressed. 
In the same study 25% of patients relapsed and 53% died with majority of them dying from 
lymphoma. Oral cavity site and stage I disease was associated with better survival outcomes 
and the following factors failed to show any association with overall survival: gender, CD4 
count, viral load, chemotherapy used and EBV status 
10
. 




The presence of a MYC/IgH rearrangement was associated with a worse overall survival 
15, 36, 
38
. This gene rearrangement is common in Burkitt’s lymphoma which is known to be a very 
aggressive B-cell lymphoma 
39
.  






The treatment of plasmablastic lymphoma should be approached in a multidisciplinary 
fashion. The overwhelming majority of these patients are HIV positive and the burden of 
disease appears to be greater in regions with a high incidence of HIV. HIV/AIDS has resulted 
in an increased economic burden on health systems in both developing and developed 
countries with the developing world bearing the brunt of this disease due to poor resources 
and infrastructure combined with large patient numbers.  
24 
 
There are no large randomised trials for the management of plasmablastic lymphoma. The 
rarity of this disease poses a unique challenge to clinicians in identifying patients at risk, 
making the diagnosis and treating the disease. As evidenced by this literature review, 
plasmablastic lymphoma has unique clinicopathological characteristics yet shares many 
clinical, pathological and immunohistochemical properties with other B-cell and plasma cell 
malignancies. 
In the absence of established standard of care guidelines the ideal management of these 
patients would be in a clinical trial setting. Currently treatment is individualised according to 
the limited evidence and resources available to the treating institution. The integration of 
HAART with chemotherapy as well as the management of opportunistic infections is very 
important; therefore it is essential to work as a multidisciplinary team with the infectious 
diseases specialists. Immunotherapy, radiotherapy and stem cell transplant can be used as per 
the treating physicians’ discretion and available resources. 
In the Sub-Saharan setting where the incidence of HIV/AIDS and consequently aggressive 
HIV associated lymphomas are high, conducting multinational randomised clinical trials will 
contribute to the knowledge base which may help in the future management of patients with 
plasmablastic lymphomas and other aggressive B-cell lymphomas. It is vitally important to 
understand the pathogenesis of this disease in order to manage it effectively. In conclusion, in 
the HIV-positive population this is a disease of severely immunosuppressed individuals. 
Optimising HIV management and improving access to antiretroviral treatment should 
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ABSTRACT 
Background: Plasmablastic lymphoma (PBL) is a highly aggressive rare subtype of diffuse 
large B-cell lymphoma first described in 1997. The diagnosis of PBL remains a challenge 
despite advances in diagnostic tools. There is no established standard of care, although CHOP 
chemotherapy is an accepted choice of treatment. The prognosis is poor even with more 
intense chemotherapy regimens. The purpose of this study is to evaluate the demographics, 
disease profile and treatment outcome of patients treated at Groote Schuur Hospital in Cape 
Town for Plasmablastic Lymphoma over a 5 year period extending from 2004 to 2009. 
Methods: Medical records of 28 patients treated for PBL between January 2004 and 
December 2009 were reviewed. Factors evaluated for the impact on overall survival (OS) 
included stage, IPI, CD4 count, chemotherapy alone vs. chemotherapy and radiotherapy, 
extranodal status and gender. Kaplan –Meier methods were used to compare patient 
outcomes including the 1 and 3 year survival proportions respectively. 
 Results: There were 25 HIV positive patients. The median age at presentation was 35 years 
(30-57) with a slight female predominance. Distribution of population by race was 80 % 
blacks, 16% mixed race and 4% whites. CHOP chemotherapy was used as the primary 
treatment in this institution and patients with early stage diseases received radiotherapy after 
chemotherapy. The objective overall response rate was 68% for HIV positive patients with a 
median OS of 52 weeks. Factors associated with good survival outcome were early stage 
disease, combination of chemotherapy with radiotherapy and low IPI score. The one and 
three years OS were 45% and 39% respectively with a relapse rate of 17% at 68 weeks on 
average. 
Conclusion: To date the survival outcome for PBL remains very poor regardless of  
intervention. In this study the primary treatment was CHOP chemotherapy which was 
combined with radiotherapy when indicated. The survival outcomes in this study were 
comparable to other studies but with a superior proportion of surviving patients 5 years post 
36 
 
treatment. Good prognosis is associated with early stage disease and treatment with a 
combination of chemotherapy and radiotherapy.  
 
Key Words: Plasmablastic Lymphoma, HIV, overall survival, CHOP chemotherapy, PBL, 
prognostic factors, IPI (International Prognostic Index) 
 





Plasmablastic lymphoma (PBL) is a highly aggressive, rare subtype of Diffuse Large B-Cell 
Lymphoma (DLBCL). This condition was first described by Delecluse et al in 1997 [1]. It is 
widely described in HIV positive patients and accounts for 2.6% of all HIV related Non-
Hodgkin lymphoma. It was first described in the oral cavity but it is now known to occur in 
other sites [2, 3].  
It occurs mostly in the middle aged population group ranging from 35-55 years [4,5]. In the 
2001 WHO classification, plasmablastic lymphoma of the oral cavity was classified in the 
category of lymphomas occurring more specifically in people who are HIV positive. 
According to the 2008 WHO classification it is now a separate category under aggressive B-
cell lymphomas [6].  This tumour has also been reported in the paediatric population with a 
few case reports documented for immunocompetent children and HIV positive children as 
well as in paediatric and adult patients in the post-transplant setting [7-10].   
There is limited data available in the literature on this malignancy. A few cases have been 
reported in HIV negative patients but most of these were immunosuppressed due to 
immunosuppressive drugs used post-transplant or chronic steroids use for autoimmune 
conditions like Crohn’s disease [9,11,12]. A few cases have been reported in 
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immunocompetent patients with no history of any known medical conditions [13]. In addition 
most reported cases are associated with Epstein-Barr virus (EBV).  The role of Human 
Herpes Virus 8 (HHV8) is not clear except in documented PBL arising in HHV-8 associated 
Multicentric Castleman’s disease [14,15]. 
The pathogenesis of PBL is poorly understood. From the available clinical, 
immunohistochemical, molecular and genetic studies it is thought that PBL arises from post-
germinal centre, terminally differentiated, activated B-cells in transition from immunoblast to 
plasma cells [16].  PBL has been shown to be morphologically and immunohistochemically 
similar to plasmablastic plasma cell myeloma (PCM) by expression of plasma markers CD38, 
CD138, VS38C, MUM1 and lack of B-cell markers like CD20. Recent studies have also 
shown that c-myc gene rearrangement which is common in Burkitt’s lymphoma may also 
play a role in more than 40% of cases [2,16-19]. 
These lymphomas are frequently resistant to therapy with poorer prognosis and death 
occurring within months after diagnosis. The introduction of HAART has led to patients with 
AIDS related lymphomas (ARL) experiencing improved survival rates and overall response 
rates. Studies have shown conflicting results in establishing clearly if the incidence of ARL’s 
has changed with the introduction of HAART [20-24]. There are no clear and validated 
treatment guidelines for plasmablastic lymphoma. The CHOP (Cyclophosphamide, 
Adriamycin, Vincristine and Prednisone) chemotherapy regimen is widely accepted as first 
line of treatment, however the NCCN guidelines  recommends more aggressive regimens like 
CODOX-M/IVAC (cyclophosphamide, vincristine, adriamycin, methotrexate, ifosfamide, 
etoposide and cytarabine) regimen, dose adjusted EPOCH (etoposide, adriamycin, 
vincristine, cyclophosphamide and prednisone) and HyperCVAD (cyclophosphamide, 
vincristine,  adriamycin, dexamethasone, methotrexate and cytarabine) [25]. Treatment 
options available for relapsed or progressive disease include palliative chemotherapy, 
palliative radiotherapy or a combination of these two treatment modalities but the outcomes 




The purpose of this study was to evaluate the treatment outcomes of patients treated for PBL 
between 2004 and 2009 by evaluating the overall survival, response rates, disease free 
survival and patient demographics. The study was also aimed at evaluating tumour and 
patient factors and how they affect treatment outcomes. 
 
Results 
Between January 2004 and December 2009, 28 patients were treated for plasmablastic 
lymphoma at Groote Schuur Hospital. The patients profile and disease characteristics is 
shown in Table 1. There were 25 (89.3%)  HIV positive and 3 (10.7%) HIV negative patients. 
The median age at presentation for all patients was 35 years (range 24-57) and the median 
follow up for all patients was 36 weeks. 
HIV Negative patients 
For the three HIV negative patients: one patient died before treatment was commenced, one 
patient died after one cycle of CHOP and the last patient progressed after five cycles of 
CHOP, then received one cycle of DHAP with progression of disease. He had palliative 
radiotherapy but died shortly after. These patients had no other known medical conditions or 
immunosuppressive conditions. They were aged 24, 34 and 48 and involved sites included 
mediastinum, brain and oral cavity. Further detailed analysis of this group of patients will not 
be described in this audit due to the small sample size.  
HIV Positive patients 
The median age at presentation was 35 (range 30-57). The median follow up was 36 weeks 
(range 3-292). There were 12 male and 13 female patients at a ratio of 1:1.08. Black patients 
accounted for 80%, mixed race patients 16% and there was one white patient (4%). 
At presentation 52% of HIV positive patients had early stage disease (stage I/II).  The 
majority of these patients (72%) presented with extranodal disease only, 4% had only nodal 
involvement and the rest of group (16%) had involvement of both nodal and extranodal sites. 
In patients with extranodal disease, 63% had only one extranodal site involved whereas 37% 
had more than one extranodal site involved. The distribution of disease by site is shown in 
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Table 2. Bone marrow involvement occurred in three patients. The most common extranodal 
sites involved were bone (21%), oral cavity and oropharynx (18%), nasopharynx and 
paranasal sinuses (18%), anorectal area and spleen at 14% per site.  
According to the International Prognostic Index,  approximately half of patients presented 
with low risk disease,  about a third presented with intermediate risk disease (low 
intermediate and high intermediate disease were considered as one group)  and only  8% of 
patients presented with high risk disease.  B-symptoms were experienced by 32% of patients 
at presentation.  The median CD4 count at presentation was 196 cells/ml³ (range 23 cells/ml³ 
to 368cells/ml³) and viral load was known in only three patients at presentation ranging from 
890 copies/ml- 70000 copies/ml.  At the time of presentation, only eight (32%) patients were 
on HAART and median time on HAART was 10 weeks (range 1-24 weeks). PBL was the 
initial manifestation of HIV/AIDS in 68% of patients whose HIV status was previously 
unknown prior to PBL diagnosis. At least 13 (52%) patients were on treatment for 
tuberculosis or had a history of tuberculosis treatment. Kaposi sarcoma was diagnosed in two 
of the 25 HIV positive patients who presented to our clinic.  
The treatment modalities included chemotherapy only in 44% of patients and chemotherapy 
plus radiotherapy in 56% of patients. The median number of chemotherapy cycles completed 
was five (range 1-8 cycles). Intrathecal chemotherapy was administered to 24% of patients 
with central nervous system (CNS) involvement or patients at risk of CNS involvement. The 
majority of patients had chemotherapy delayed during their treatment due to severe 
neutropenia or complications from PTB or HIV treatment. For the 14 patients who received 
radiotherapy, half of them received IFRT (dose range 20Gy-40Gy) and the other half of 
patients received palliative radiotherapy (dose range 8Gy-30Gy) for progressive or relapsed 
disease.  
Patients who completed the initial intended treatment were evaluated for treatment response. 
As shown in Table 3; 76% of HIV positive patients were evaluable. The remaining patients 
were either lost to follow up or died before completing the initial intended treatment with no 
record of the achieved response. Complete response was achieved in the majority of patients. 
A partial response was seen in one patient whereas 32% of patients progressed on treatment. 
For those patients who progressed on chemotherapy, three were offered palliative 
radiotherapy with doses ranging from 8 Gy to 20 Gy and one patient received palliative CMV 
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(Cyclophosphamide, Methotrexate and Vincristine) chemotherapy. Relapses were seen in 
only two (17%) patients at 12 weeks and 123 weeks after completion of treatment. The first 
patient relapsed at the initial primary site in the nasopharynx and brain and was subsequently 
treated with palliative CMV chemotherapy and palliative whole brain radiotherapy (WBRT) 
to 20Gy. The other patient’s primary disease was in the liver, spleen and oral cavity and 
relapsed in the left cervical node and was subsequently offered palliative chemotherapy and 
died after one cycle of chemotherapy.  
The Kaplan-Meier curves for overall survival and the impact of the analysed factors are 
shown in Figure 2 and Figure 3. 
As shown in Figure 2 the estimated overall survival of HIV positive patients at 1 year and 3 
years was 45% and 39% respectively.  
At the time of analysis of this cohort, five (25%) patients were still known to be alive. These 
patients were more than five years post treatment. Only two of the surviving patients were 
still being followed up, the other three patients were lost to follow up. Records from the 
South African Department of Home Affairs however proved the three patients lost to follow 
up were still alive. 
The following factors were analysed to evaluate their impact on overall survival: stage, IPI, 
CD4 count, chemotherapy alone vs. chemotherapy and radiotherapy, extranodal status and 
gender.  
For the above factors stage I/II showed better OS than stage III/IV with  1 year OS of 63% 
and 23% respectively and  3 years OS of 50% and 11% respectively (p=0.045) as shown in 
Figure 3A. The IPI when comparing low risk disease with intermediate disease showed a 1 
year OS of 58% and 25% respectively and 3 year OS of 58% and 13% respectively 
(p=0.040). The 1 year OS for patients treated with chemotherapy alone versus chemotherapy 
and radiotherapy were 18% and 57% respectively and 3 years OS were 0% and 56% 
respectively  (p=0.021) in favour of chemotherapy followed by radiotherapy. This 
statistically significant p-value included patients treated with IFRT after complete response 
and palliative radiotherapy for partial response and progressive disease. Graph 3F shows that 
patients with low risk disease had better OS than patients with intermediate risk disease with 
a 1 year OS of 57% and 27% respectively and a 3 year OS of 57% and 13% respectively 
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(p=0.040). As shown in Graph 3E, there was a positive trend towards better OS for patients 
with CD4>200 cells/ml³ compared to those with a CD4<200 cells/ml³ although the p-value 
was not statistically significant (p=0.42). Gender did not impact on OS as shown in Figure 
3D. The number of extranodal sites involved also did not show any statistically significant 
impact on OS (p=0.57), however for patients with only one extranodal site there was a 
positive trend after approximately two years of follow up. 
 
Discussion 
In this cohort we evaluated 28 patients who presented at Groote Schuur Hospital between 
January 2004 and December 2009 with a histological diagnosis of Plasmablastic Lymphoma. 
PBL is a variant of DLBCL which was recognised as a separate entity and described by 
Delecluse et al in 1997 [1]. This type of lymphoma is associated with HIV/AIDS infection. 
South Africa has a high HIV/AIDS prevalence.  According to the Midyear Population 
Estimates 2011 report by Statistics South Africa, the estimated overall HIV prevalence rate is 
10.6% with a total of 5.38 million people living with HIV in 2011. An estimated 16.6% of the 
adult population aged 15-49 years of age is HIV positive [26].  With these high national 
HIV/AIDS prevalence rates a significant number of HIV related lymphomas like DLBCL, 
Burkitt’s lymphoma and PBL are diagnosed  [27,28] . 
Despite the improvements in diagnosis by modern techniques including 
immunohistochemistry and other newer tools and the introduction of more intense 
chemotherapy regimens, the diagnosis and treatment of PBL still remains challenging. The 
overall survival rates and relapse rates still remain disappointingly poor. 
This rare HIV related lymphoma makes up 2.6% of all HIV related Non-Hodgkin 
lymphomas. The true incidence is unknown due to its rarity and the lack of large trials [2,3]. 
Since this group was overwhelmingly dominated by HIV positive patients, the discussion will 
mainly focus in PBL in the setting of HIV. In our study the median age at presentation for 
HIV positive patients was 35 years which is consistent with other studies and case reports 
[16,29-32].  In these studies there was a slight male predominance. In our study there was 
slight female predominance. This observation is consistent with the HIV prevalence in South 
Africa which shows a female predominance. When looking at the HIV distribution by race in 
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our cohort, most of patients were black, a few of the patients were mixed race and only a 
minority of patients were whites.  This is consistent with the national racial breakdown [26].  
Patients living with HIV/AIDS are at an increased risk of developing HIV related lymphomas 
[33]. The pathogenesis of PBL is multifactorial. Although typically associated with HIV 
infection, Castillo and his colleagues reported on the largest known cohort of PBL in HIV 
negative patients. They noted distinct clinopathological characteristics such as short OS, 
lower rates of oral involvement and EBV association [34].  Most of their patients had other 
immunosuppressive conditions including autoimmune diseases and solid organ transplants, 
but in some cases no cause of immunosuppression was identified. The HIV negative patients 
in this study had no known immunosuppressive conditions and all died of lymphoma. 
EBV has also been associated with pathogenesis. Several authors have reported more than 
70% association with EBV [32,35-37]. In this study EBV was not tested for as it is not 
essential for diagnosis. The role played by EBV in the pathogenesis of HIV related 
lymphoproliferative disorders is still a subject of debate. It is believed that EBV encodes a 
series of products interacting with or exhibiting homology to a wide variety of antiapoptotic 
molecules, cytokines and signal transducers and therefore promoting EBV infection, 
immortalization and malignant transformation [37,38].  
Plasmablastic lymphoma may be aetiologically related to plasmacytoma e.g.  Qing and 
colleagues reported a case where PBL occurred as a result of transformation from a 
plasmacytoma [39]. This association of PBL with plasma cell myelomas was studied by a 
number of authors who demonstrated immunophenotypic similarities between PBL and 
plasma cell myeloma [18]. However, Chung Che and colleagues reported that PBL was more 
similar to DLBCL immunohistochemically than to plasma cell myeloma [17].   
In the initial reports, PBL was described in the oral cavity and hence the name PBL of the 
oral cavity. New cases have been reported since 1997 which were considered pathologically 
to be PBL but occurring extraorally. These studies indicated that PBL is very heterogeneous 
and may occur in several extraoral sites including the gastrointestinal system, paranasal 
sinuses, nasopharynx, skin, central nervous system, lymph nodes, subcutaneous tissues and 
other organs. This led to the nomenclature being changed to plasmablastic lymphoma 
[32,38]. In this study there was significant heterogeneous site involvement including the oral 
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cavity, oropharynx, gastrointestinal and other sites rarely reported in the literature including 
kidney, liver, ascites, pleural effusion and mediastinum (Table 3). 
In an editorial comment by Pantanowitz and Dezube (2007) entitled ‘Plasmablastic 
Lymphoma, A diagnostic and Therapeutic Puzzle’, the authors attempted to summarise the 
diagnostic and therapeutic challenges in PBL management. These challenges have not been 
met two decades after PBL was first described.  The standard treatment has not been 
established to date although CHOP chemotherapy is widely accepted as first line therapy. The 
NCCN recommends more aggressive therapeutic regimens [25].  A number of other 
treatment options have been explored. Bibas and colleagues in a single institution experience 
used the proteozome inhibitor bortezomib which is indicated for the treatment of multiple 
myeloma alone or in combination with dexamethasone, oxaliplatin, gemcitabine, cytosine 
arabinose and pegfilgrastim (GOVDD). The authors reported that this was an effective and 
manageable therapeutic option in HIV associated PBL but they failed to show an overall 
survival benefit [40].  Other treatment options evaluated in the literature include the anti-
CD20 monoclonal antibody Rituximab which showed a reasonable response in patients with 
minimal or partial CD20 expression [16,17]. There are no randomised controlled studies 
comparing standard CHOP chemotherapy with the more aggressive regimens. Single 
institutional experiences have not demonstrated any superiority of the more aggressive 
regimens to CHOP chemotherapy. The evidence for effectiveness of high dose salvage 
chemotherapy and stem cell transplant in PBL is scanty but since it was shown to be effective 
in DLBCL, some authors suggest that it may be a viable option in first remission [31,40,41]. 
These differences in opinions may exemplify the unique clinicopathologic features of PBL.  
The impact of HAART on the treatment and prognosis of HIV related lymphomas has been 
an area of research and debate but it has now been accepted that HAART improves treatment 
outcomes in HIV/AIDS related lymphomas with even some reported cases of spontaneous 
regressions of PBL on HAART [42-45]. In this study all patients were commenced on 
HAART before chemotherapy was commenced and five patients are alive at more than five 
years since diagnosis of PBL. A third of patients were on HAART at presentation and the rest 
were initiated prior to commencement of chemotherapy unless there was a life threatening 




Standard CHOP was used in the majority of patients. More than 68% of the HIV positive 
group attained a complete or a good partial response to chemotherapy. This was comparable 
to results reported in other studies [31,32,34,45]. Most patients had low or intermediate risk 
disease according to the IPI and only a few patients had high risk disease. The treatment 
outcomes remain poor. The above studies also demonstrated that patients treated for PBL 
regardless of chemotherapy regimen used have been shown to achieve high response rates but 
tend to relapse very early from within a few weeks to a few months post treatment with most 
patients dying within the first year after diagnosis. Similarly most of our patients died within 
the first year after diagnosis. In this cohort only a minority of patients were documented to 
have relapsed after achieving complete response however most patients with documented 
complete response were lost to follow up. In the South African context it may be speculated 
that the poor outcomes may be attributed to severe immunosuppression, poor general 
condition at presentation, presence of other comorbidities including tuberculosis, possible 
drug interactions with tuberculosis treatment and treatment delays due to various reasons. 
More than 60% of the HIV-positive cohort had treatment delays with some patients 
experiencing multiple chemotherapy delays. These treatment delays were due to poor 
treatment tolerance, toxicity especially severe pancytopenia and poor compliance. During the 
period when these patients were treated, growth colony stimulating factors (GCSF) were not 
freely available at our institution.   
In this cohort, the median OS for HIV positive patients was 13 months. In a study by Castillo 
and his colleagues entitled ‘Prognostic factors in chemotherapy treated patients with HIV-
associated lymphoma’ their findings were a median OS of 14 months and a 5 year OS of 31% 
[31].  These results were similar and comparable to this cohort. 
A study by Montes-Moreno in a population of HIV positive patients reported disease free 
survival of around 42% at five years [46]. These results, although not reproduced in other 
studies also show a pattern of early relapse and poor survival outcomes as observed in the 
current study. 
Little is known about the potential impact of any prognostic factors on survival outcomes. In 
this cohort early stage and chemotherapy followed by radiotherapy demonstrated a positive 
impact on prognosis. This positive trend was also noted in radiotherapy given as palliation 
therefore signalling a potential role for palliative radiotherapy in the management of relapsed 
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or progressive disease. The IPI was a good predictor of outcome in the low risk disease 
versus intermediate disease but it may need to be adapted for HIV related PBL as the 
prognostic groupings appears to be different to that of DLBCL. The possible explanation to 
this positive impact on survival outcomes by these factors may be due the fact that these were 
early disease patients. These patients also received radiotherapy after completion of 
chemotherapy which may have impacted on the results. 
Gender, number of extranodal sites involved and CD4 count did not affect survival outcomes. 
Patients who presented with a CD4 count of >200 cells/ml³ however did show a trend 
towards better survival. The CD4 level of <200 cells/ml³ was chosen because that was the 
value used to initiate HAART at the time that the patients were treated in this study. In other 
studies improved OS was associated with achieving a complete response and the use of 
concurrent HAART with chemotherapy. These factors were not evaluated in the current 
study.  Similarly EBV status, sex, primary site of involvement, clinical stage, and CD4 count 





In this cohort of 28 patients treated for Plasmablastic Lymphoma between January 2004 and 
December 2009, the survival outcomes as well as the patient demographics and disease 
profiles were reviewed.  
Slightly more than half of the patients presented with early disease. The population of 
patients in this cohort displayed a wide heterogeneous site involvement. Only a third of 
patients had B-symptoms at presentation and a tenth of the patients had bone marrow 
involvement.  
At Groote Schuur Hospital CHOP chemotherapy remains the treatment of choice for PBL. 
The treatment outcomes reported in the current study are comparable with other studies. The 
patients in this study displayed high overall response rates but generally poor treatment 
outcomes as described in other studies. Patients who presented with early stage disease, low, 
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intermediate risk disease and who received radiotherapy after chemotherapy showed a better 
overall survival.  
Several studies have failed to establish prognostic factors in PBL. In this study early disease 
presentation and the use of radiotherapy was shown to improve survival outcomes.  
The diagnosis and treatment of PBL remains a challenge and therefore early diagnosis and 
treatment of PBL like other lymphomas is very crucial so as to achieve good survival rates. 
To further establish standard care guidelines large multi institutional randomised trials are 
required but due to the rarity of PBL, this may not be feasible. 
 
Materials and Methods 
Folders for patients treated for PBL between 2004 and 2009 were retrospectively reviewed. 
The list for these patients was obtained from the Groote Schuur Hospital Radiation Oncology 
Department.  Ethics approval was obtained from the Health and Research Ethics Committee 
of the University of Cape Town and permission from the Clinical Director of Groote Schuur 
Hospital was obtained before commencement of the study.  A literature review was 
performed using Pubmed, Google, available journals and text books. 
All folders reviewed included only patients over the age of 18 years with a confirmed 
histological diagnosis of PBL. The data extracted was recorded into customised data sheets 
and transferred into an excel spreadsheet.  
The data collected included age at diagnosis, date of presentation, gender, ethnic group, site 
of disease, stage of disease, ECOG performance status, lactate dehydrogenase (LDH) and the 
International Prognostic Index (IPI). The IPI was calculated by incorporating the following 
factors; age >60 years, serum lactate dehydrogenase (LDH) levels >1x normal, ECOG 
performance status of 2-4, stage III or IV and >1 extranodal site involvement. The presence 
of B-symptoms which included weight loss of >10% in the last 6 months, unexplained fever 
or night sweats was noted. 
In addition to the above, HIV status, CD4 count and viral load when available were included 
in the data sheet as well as the presence of any infections like pulmonary tuberculosis (PTB), 
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varicella zoster and other malignancies like Kaposi sarcoma. Time on HAART at diagnosis 
was also recorded.  
The treatment approach was documented including the chemotherapy regimen used, number 
of cycles completed and radiotherapy doses for those patients who received radiotherapy. 
Responses to treatment were recorded as complete response (CR), partial response (PR) and 
progressive disease (PD). For patients who achieved a complete response and relapsed, the 
time to relapse, site of relapse and the treatment offered for the relapse was documented. 
Complete response was defined as the clinically or radiological disappearance of all evidence 
of disease. Partial response was described as regression of measurable disease with no new 
sites and progressive disease was defined as evidence of new lesions or more than 50% 
increase in previously involved sites from nadir [48].  
 
At last follow up, the patients’ status was recorded as either alive with disease, alive without 
disease or dead, and if recorded as dead it was noted whether they died from lymphoma or 
other causes. 
At initial presentation, all the patients had a histological diagnosis of plasmablastic 
lymphoma. A detailed history and clinical examination was done. Staging investigations 
consisted of a biochemical and haematological profile including a full blood count, renal 
function tests, liver function tests and LDH levels.  An HIV test was performed in those 
patients with unknown HIV status. A CT scan of the neck, chest abdomen and pelvis and a 
bone marrow aspiration and trephine (BMAT) were done.  PET/CT was not utilised for 
staging in this study. Patients were staged using the Cotswold Modified Ann Arbor staging 
system. 
All patients who were not yet on HAART at presentation were referred to the infectious 
disease unit for counselling and commencement of HAART. 
The chemotherapy regimen used for all patients was CHOP chemotherapy initially with the 
intention to give five cycles followed by restaging investigations and to continue on 
chemotherapy depending on response. Intrathecal (IT) chemotherapy using methotrexate, 
cytosine arabinosine and dexamethasone was administered to patients at risk of central 
nervous spread e.g. brain or spinal cord involvement, paratesticular sites, parameningial sites 
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etc. Patients with pancytopenia prior to commencement of chemotherapy received 
Bleomycin, Vincristine and Prednisone (BOP) chemotherapy until pancytopenia resolved. 
Patients with a poor performance status received a reduced dose of CHOP until their clinical 
condition stabilised and one patient with cardiac related problems received etoposide, 
cytosine arabinosine and methyprednisolone. Some patients received Involved Field 
Radiotherapy (IFRT) or palliative radiotherapy as indicated as per treating physician 
discretion. Those who progressed on chemotherapy or relapsed were treated with palliative 
chemotherapy with or without palliative radiotherapy depending on the sites of disease. The 
palliative chemotherapy regimen used consisted of low dose Cyclophosphamide, 
Methotrexate and Vincristine (CMV).  
 HIV positive patients do not qualify for high dose salvage chemotherapy and stem cell 
transplant at our institution due to lack of resources. The HIV negative patient who 
progressed on CHOP received salvage therapy with DHAP (cisplatin, cytosine arabinosine 
and dexamethasone). 
Patients who completed therapy were followed up 3 monthly for the first year then 4-6 
monthly for three years and annually thereafter. The disease status was evaluated by history, 
clinical examinations, full blood count and blood chemistry especially LDH. Imaging, biopsy 
and any other investigations were only considered as per clinician’s discretion and clinical 
findings. 
Statistical analysis was performed using GraphPad Prism version 6 for Windows. Overall 
Survival was calculated from time of registration to time of death due to lymphoma or any 
other cause or date last seen for patients lost to follow up. Progression Free Survival (PFS) 
was calculated from time of registration to time of first progression on primary treatment, 
death or date last seen for those patients lost to follow up. Survival curves were generated 
using the Kaplan-Meier method and compared using the log rank test. A p value of <0.05 was 
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 IFRT: involved field radiotherapy 
 IT: intrathecal chemotherapy 
 ECOG: Eastern Cooperative Oncology Group 
 HAART: highly active antiretroviral therapy 
 PBL: plasmablastic lymphoma 
 HIV: Human Immunodeficiency Virus 




 Dr Sebathu P Chiyapo declares no competing interests. No funding or fees were received in 
any form in the preparation of this manuscript 
Dr Zainab Mohamed declares no competing interests. No funding or fees were received in 
any form in the preparation of this manuscript 
 
 
Authors Contribution  
Dr Sebathu P Chiyapo 
Was responsible for the literature research, data analysis, write up of the manuscript 
50 
 
Dr Zainab Mohamed 
Was responsible for supervision, data analysis and editing of the manuscript 
Authors' information 
Dr SPC is a radiation oncology resident at the Department of Radiation Oncology at Groote 
Schuur Hospital in Cape Town, South Africa. He holds an MB.BS from the University of the 
West Indies in Trinidad and Tobago and he is a Fellow of the College of Radiation 
Oncologist of South Africa. 
Dr ZM is a Senior Specialist in the Radiation Oncology Department, Groote Schuur Hospital, 
and University of Cape Town. She obtained her undergraduate degree (MBChB) at the 
University of Cape Town in 1992 and her MMed in Radiation Oncology at the University of 




I am thankful to all people who supported me in this journey. I have successfully completed 
my research project. 
 Firstly my wife Tebogo Chiyapo and my daughter Oaratwa Chiyapo for 
understanding and giving me support and all the help I needed and believed in me 
even during times when I did not really believe in myself. 
 My supervisor Dr Zainab Mohamed for her valuable insight and support and guidance 
throughout the whole process 
 Dr Alister Hunter for his input, guidance and support 
 To all my radiation oncology colleagues and staff for all their support 
 The staff at the filing office who ensured that I had all the patients folders that I 
needed to evaluate 
 I am also thankful to my mother Ms Wapiwa Samson and my in-laws who  gave me 
support and encouraged me to carry on 
51 
 
This journey would not have been easy if it was not for the support and dedication you all 
have shown to me. I pray to God the Almighty to give you all his blessings and keep you safe 


























1. Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al: Plasmablastic lymphomas of the 
oral cavity: A new entity associated with the human immunodeficiency virus infection. Blood 
89:1413-1420, 1997  
2. Boy SC, van Heerden MB, Babb C, et al: Dominant genetic aberrations and coexistent 
EBV infection in HIV-related oral plasmablastic lymphomas. Oral Oncol 47:883-887, 2011  
3. Tsachouridou O, Christoforidou A, Metallidis S, et al: Plasmablastic lymphoma of the oral 
cavity, a B cell-derived lymphoma associated with HIV infection: A case series. Eur Arch 
Otorhinolaryngol 269:1713-1719, 2012  
4. Jaffe ES, Pittaluga S: Aggressive B-cell lymphomas: A review of new and old entities in 
the WHO classification. Hematology Am Soc Hematol Educ Program 2011:506-514, 2011  
5. Folk GS, Abbondanzo SL, Childers EL, et al: Plasmablastic lymphoma: A 
clinicopathologic correlation. Ann Diagn Pathol 10:8-12, 2006  
6. Radhakrishnan R, Suhas S, Kumar RV, et al: Plasmablastic lymphoma of the oral cavity in 
an HIV-positive child. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100:725-731, 
2005  
7. Hernandez C, Cetner AS, Wiley EL: Cutaneous presentation of plasmablastic post-
transplant lymphoproliferative disorder in a 14-month-old. Pediatr Dermatol 26:713-716, 
2009  
8. Gogia A, Bakhshi S: Plasmablastic lymphoma of oral cavity in a HIV-negative child. 
Pediatr Blood Cancer 55:390-391, 2010  
53 
 
9. Zimmermann H, Oschlies I, Fink S, et al: Plasmablastic posttransplant lymphoma: 
Cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome 
in the prospective german posttransplant lymphoproliferative disorder registry. 
Transplantation 93:543-550, 2012  
10. Plaza R, Ponferrada A, Benito DM, et al: Plasmablastic lymphoma associated to Crohn's 
disease and hepatitis C virus chronic infection. J Crohns Colitis 5:628-632, 2011  
11. Plaza R, Ponferrada A, Benito DM, et al: Plasmablastic lymphoma associated to Crohn's 
disease and hepatitis C virus chronic infection. J Crohns Colitis 5:628-632, 2011  
12. Thakral C, Thomas L, Gajra A, et al: Plasmablastic lymphoma in an immunocompetent 
patient. J Clin Oncol 27:e78-81, 2009  
13. Guan B, Zhang X, Hu W, et al: Plasmablastic lymphoma of the oral cavity in an HIV-
negative patient. Ann Diagn Pathol 15:436-440, 2011  
14. Ferrazzo KL, Mesquita RA, Aburad AT, et al: EBV detection in HIV-related oral 
plasmablastic lymphoma. Oral Dis 13:564-569, 2007  
15. Dupin N, Diss TL, Kellam P, et al: HHV-8 is associated with a plasmablastic variant of 
castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406-
1412, 2000  
16. Castillo JJ, Reagan JL: Plasmablastic lymphoma: A systematic review. Scientific World 
Journal 11:687-696, 2011  
54 
 
17. Chang CC, Zhou X, Taylor JJ, et al: Genomic profiling of plasmablastic lymphoma using 
array comparative genomic hybridization (aCGH): Revealing significant overlapping 
genomic lesions with diffuse large B-cell lymphoma. J Hematol Oncol 2:47, 2009  
18. Vega F, Chang CC, Medeiros LJ, et al: Plasmablastic lymphomas and plasmablastic 
plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806-
815, 2005  
19. Pantanowitz L, Dezube BJ: Editorial comment: Plasmablastic lymphoma--a diagnostic 
and therapeutic puzzle. AIDS Read 17:448-449, 2007  
20. Mbulaiteye SM, Parkin DM, Rabkin CS: Epidemiology of AIDS-related malignancies an 
international perspective. Hematol Oncol Clin North Am 17:673-96, v, 2003  
21. Rabkin CS, Testa MA, Huang J, et al: Kaposi's sarcoma and Non-Hodgkin's lymphoma 
incidence trends in AIDS clinical trial group study participants. J Acquir Immune Defic 
Syndr 21 Suppl 1:S31-3, 1999  
22. Ledergerber B, Telenti A, Egger M: Risk of HIV related Kaposi's sarcoma and non-
hodgkin's lymphoma with potent antiretroviral therapy: Prospective cohort study. Swiss HIV 
cohort study. BMJ 319:23-24, 1999  
23. Buchbinder SP, Holmberg SD, Scheer S, et al: Combination antiretroviral therapy and 
incidence of AIDS-related malignancies. J Acquir Immune Defic Syndr 21 Suppl 1:S23-6, 
1999  
24. Jacobson LP, Yamashita TE, Detels R, et al: Impact of potent antiretroviral therapy on the 
incidence of Kaposi's sarcoma and Non-Hodgkin's lymphomas among HIV-1-infected 
55 
 
individuals. multicenter AIDS cohort study. J Acquir Immune Defic Syndr 21 Suppl 1:S34-
41, 1999  
25. NCCN clinical practice guidelines in oncology: Non-hodgkin's lymphoma, version 
3.2012. available online at: 
http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#nhl . Accessed on 
September 30 2012 





d6ba3ae6d790&biw=1366&bih=643 . Accessed September 30 2012 
27. Abayomi EA, Somers A, Grewal R, et al: Impact of the HIV epidemic and anti-retroviral 
treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South 
Africa, 2002-2009: Preliminary findings of the Tygerberg lymphoma study group. Transfus 
Apher Sci 44:161-166, 2011  
28. Ulrickson M, Press OW, Casper C: Epidemiology, diagnosis, and treatment of HIV-
associated Non-Hodgkin lymphoma in resource-limited settings. Adv Hematol 2012:932658, 
2012  
29. Khan MA, Jakate S, Komanduri S: Rare AIDS-associated plasmablastic lymphoma as the 
initial presentation of AIDS. Clin Adv Hematol Oncol 8:55-57, 2010  
30. Porter SR, Diz Dios P, Kumar N, et al: Oral plasmablastic lymphoma in previously 
undiagnosed HIV disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 87:730-734, 
1999  
56 
31. Castillo JJ, Winer ES, Stachurski D, et al: Prognostic factors in chemotherapy-treated
patients with HIV-associated plasmablastic lymphoma. Oncologist 15:293-299, 2010 
32. Castillo J, Pantanowitz L, Dezube BJ: HIV-associated plasmablastic lymphoma: Lessons
learned from 112 published cases. Am J Hematol 83:804-809, 2008 
33. Powles T, Matthews G, Bower M: AIDS related systemic Non-Hodgkin's lymphoma. Sex
Transm Infect 76:335-341, 2000 
34. Castillo JJ, Winer ES, Stachurski D, et al: HIV-negative plasmablastic lymphoma: Not in
the mouth. Clin Lymphoma Myeloma Leuk 11:185-189, 2011 
35. Carbone A: Emerging pathways in the development of AIDS-related lymphomas. Lancet
Oncol 4:22-29, 2003 
36. Oudejans JJ, Jiwa NM, van den Brule AJ, et al: Epstein-Barr virus and its possible role in
the pathogenesis of B-cell lymphomas. Crit Rev Oncol Hematol 25:127-138, 1997 
37. Carbone A, Gloghini A, Dotti G: EBV-associated lymphoproliferative disorders:
Classification and treatment. Oncologist 13:577-585, 2008 
38. Rezk SA, Weiss LM: Epstein-Barr virus-associated lymphoproliferative disorders. Hum
Pathol 38:1293-1304, 2007 
39. Qing X, Sun N, Chang E, et al: Plasmablastic lymphoma may occur as a high-grade
transformation from plasmacytoma. Exp Mol Pathol 90:85-90, 2011 
40. Bibas M, Grisetti S, Alba L, et al: Patient with HIV-associated plasmablastic lymphoma
responding to bortezomib alone and in combination with dexamethasone, gemcitabine, 
57 
oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol 
28:e704-8, 2010  
41. Castillo JJ: Plasmablastic lymphoma: Are more intensive regimens needed? Leuk Res
35:1547-1548, 2011 
42. Navarro WH, Kaplan LD: AIDS-related lymphoproliferative disease. Blood 107:13-20,
2006 
43. Nasta SD, Carrum GM, Shahab I, et al: Regression of a plasmablastic lymphoma in a
patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma 43:423-426, 2002 
44. Lester R, Li C, Phillips P, et al: Improved outcome of human immunodeficiency virus-
associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral 
therapy: A report of two cases. Leuk Lymphoma 45:1881-1885, 2004  
45. Guan B, Zhang X, Ma H, et al: A meta-analysis of highly active anti-retroviral therapy for
treatment of plasmablastic lymphoma. Hematol Oncol Stem Cell Ther 3:7-12, 2010 
46. Montes-Moreno S, Gonzalez-Medina AR, Rodriguez-Pinilla SM, et al: Aggressive large
B-cell lymphoma with plasma cell differentiation: Immunohistochemical characterization of
plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic 
phenotype. Haematologica 95:1342-1349, 2010  
47. Teruya-Feldstein J, Chiao E, Filippa DA, et al: CD20-negative large-cell lymphoma with
plasmablastic features: A clinically heterogenous spectrum in both HIV-positive and -
negative patients. Ann Oncol 15:1673-1679, 2004  
58 
48. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant
lymphoma. J Clin Oncol 25:579-586, 2007  
59 
Tables and Figures 
Table 1. Patient’s demographics and disease characteristics 
Profile HIV +ve Patients 
n=25 
Age 
      Mean 
      Median 





     Male 




      Black 
      White 
      Coloured 
20(80%) 
1(4%) 
   4 (16%) 
Stage 
    I/II 
    III/IV 
   Nodal only 
   Extranodal only 
   Extranodal + nodal 










     Low risk 0-1 
     Intermediate 2-3 
      High risk 4-5 
14(56%) 
9(36%) 







     Median 




    Chemotherapy alone 
    Chemo + RT 
    Median RT Dose 






Figure 1: Treatment Summary all patients 
• Treatment Not 
Comple ted 21 % 
Treatment Summary 
n=28 




Table 2: Disease distribution by site in all patients 
Site Percentage  of patients 
Bone 21% 
Oral cavity, oropharynx 18% 
Nasopharynx and Sinuses 18% 
Spleen 14% 
Anorectum 14% 
Bone Marrow 11% 
Liver 11% 
Exradural, Cerebrospinal fluid and Brain 11% 
Lymph nodes 11% 
scalp 7% 
Mediastinum 4% 
Skin and subcutaneous 4% 
Kidney 4% 
*Other 14% 
*pleural effusion, ascites, unspecified site
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CR 12(57%) 12(63%) 
PR 1(5%) 1(5%) 
PD 8(38%) 6(32%) 
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Figure 2.   Overall Survival in all HIV Positive patients 
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Figure 3: Survival curves comparing different factors and their impact on survival in 
HIV positive patients 
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I. Data Capture Instruments
DATA ENTRY FORM 
1. Patient Demographics
Initials 





Age at presentation 
Date of Presentation 
Date of Commencement of Treatment 
2. Disease Site
3. Tumor EBV status
Positive Negative Unknown 
5. HIV Status
Positive Negative Unknown 
If Positive 
CD4 count Viral load 
67 
6. Stage




Age > 60 
Performance Status 2-4 
Extranodal Involvement Site 
Serum LDH>1.5x normal 
Stage III or IV disease 
IPI 
8. 
Months since HIV diagnosis 
Months  on ARV’s at Diagnosis 
9. Opportunistic Infections
10. Other Malignancies
11. For HIV negative





No of cycles Type / Dose 
13. Restaging
Timing Of Restaging Investigations 
14. Completion of Intended Primary Treatment
Yes 
No 
If No, Why? 
___________________________________________________________________________
___________________________________________________________________________ 
15. Response to primary treatment








17. Treatment of Relapse
Salvage chemo Radiotherapy Palliation 
Type 
Completion of Salvage Chemo 




Alive and free of disease 
Alive with disease 
Lost to follow up 
Dead 





19. Disease Free Survival
Date of Treatment Start Date of relapse Date last seen 





Date of Treatment Start Date of Death Date last seen 
Time till Death: _________________________ 





II: OFFICIAL ETHICS APPROVAL LETTERS: 
Department of Radiation Oncology 
Groote Schuur Hospital 
Cape Town 
      16
th
 March 2012 
The Ethics Committee 
Groote Schuur Hospital 
Cape Town 
Dear Sir/Madam 
Request for Expedited Review of College Commentary / Mmed for Radiation Oncology. 
I plan to do a retrospective review on patients treated in Groote Schuur Hospital between 2004 and 
2009 for Plasmablastic Lymphoma in both HIV negative and HIV positive patients.  My end points 
will be overall survival, disease free survival, relapse rates.  
This will entail a retrospective review of patient records. Strict patient confidentiality will be 
maintained and there will be no disclosure of patient details. There will be no patient contact. Patients 
will remain anonymous. 
I hereby request an expedited review of this college commentary/Mmed mini thesis for radiation 
oncology. 
Yours sincerely, 
Dr. Sebathu P Chiyapo 
Radiation Oncology Department 
NB. Dr Z. Mohamed had previously requested ethics approval to do the research project which was 
approved on 22 November 2010, the approval expired on 30
th
 November 2011 and the reference 
number was HREC: 555/2010 
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Enquiries : Dr. Sebathu. P Chiyapo 
Telephone : (021) – 404-4276 
Fax : 
E-mail : sebathuspc@hotmail.com 
Reference : 
Date : 19th April 2012 
Dr. B. Patel 
Chief Medical Superintendent 
Clinical Directorate 
G45, OMB 
Groote Schuur Hospital 
Observatory 
7925 
Dear Dr Patel, 
 Re: Audit project:  “A Retrospective Study of Patients Treated for Plasmablastic
Lymphoma Between 2004 and 2009 in Groote Schuur Hospital”
I hereby wish to apply for permission to perform an audit study, of the above title, in the 
Radiation Oncology Department of this hospital. It is a requirement of the MMed degree/ 
College exam (FRC Rad Onc.) 
This project will involve an audit of radiotherapy folders only; patients will not be 
contacted or interviewed. 
Our Departmental Research Committee has approved the study, as well as the 
Research Ethics Committee. The HREC. REF is 181/2012. I have included a copy of 
my study proposal and ethics approval letter. 
I shall therefore be grateful to receive your approval, as the member of the Clinical 
Directorate responsible for research projects at Groote Schuur Hospital, to proceed with 
this study. Please let me know if any other documentation is required 
Thank you  
Sincerely 
Dr Sebathu P Chiyapo 
(Registrar,  
Dept Radiation Oncology) 
LE 32 Clinics 
Departement van Gesondheid 
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II. Guidelines to Authors for Submission to the
Journal of Hematology & Oncology
Instructions for authors 
Research Articles 
Submission process | Preparing main manuscript text | Preparing illustrations and figures | 
Preparing tables | Preparing additional files | Style and language  
See 'About this journal' for descriptions of different article types and information about policies and 
the refereeing process. 
Submission process 
Manuscripts must be submitted by one of the authors of the manuscript, and should not be 
submitted by anyone on their behalf. The submitting author takes responsibility for the article 
during submission and peer review.  
Please note that Journal of Hematology & Oncology levies an article-processing charge on all 
accepted Research Articles; if the submitting author's institution is a BioMed Central member the 
cost of the article-processing charge may be covered by the membership (see About page for detail). 
Please note that the membership is only automatically recognised on submission if the submitting 
author is based at the member institution.  
To facilitate rapid publication and to minimize administrative costs, Journal of Hematology & 
Oncology prefers online submission.  
Files can be submitted as a batch, or one by one. The submission process can be interrupted at any 
time; when users return to the site, they can carry on where they left off. 
See below for examples of word processor and graphics file formats that can be accepted for the 
main manuscript document by the online submission system. Additional files of any type, such as 
movies, animations, or original data files, can also be submitted as part of the manuscript.  
During submission you will be asked to provide a cover letter. Use this to explain why your 
manuscript should be published in the journal, to elaborate on any issues relating to our editorial 
policies in the 'About Journal of Hematology & Oncology' page, and to declare any potential 
competing interests. You will be also asked to provide the contact details (including email addresses) 
of potential peer reviewers for your manuscript. These should be experts in their field, who will be 
able to provide an objective assessment of the manuscript. Any suggested peer reviewers should not 
have published with any of the authors of the manuscript within the past five years, should not be 
current collaborators, and should not be members of the same research institution. Suggested 
reviewers will be considered alongside potential reviewers recommended by the Editor-in-Chief 
and/or Editorial Board members.  
78 
 
Assistance with the process of manuscript preparation and submission is available from BioMed 
Central customer support team. 
We also provide a collection of links to useful tools and resources for scientific authors on our Useful 
Tools page. 
File formats 
The following word processor file formats are acceptable for the main manuscript document:  
 Microsoft word (DOC, DOCX) 
 Rich text format (RTF) 
 Portable document format (PDF) 
 TeX/LaTeX (use BioMed Central's TeX template) 
 DeVice Independent format (DVI) 
TeX/LaTeX users: Please use BioMed Central's TeX template and BibTeX stylefile if you use TeX 
format. During the TeX submission process, please submit your TeX file as the main manuscript file 
and your bib/bbl file as a dependent file. Please also convert your TeX file into a PDF and submit this 
PDF as an additional file with the name 'Reference PDF'. This PDF will be used by internal staff as a 
reference point to check the layout of the article as the author intended. Please also note that all 
figures must be coded at the end of the TeX file and not inline. 
If you have used another template for your manuscript, or if you do not wish to use BibTeX, then 
please submit your manuscript as a DVI file. We do not recommend converting to RTF. 
For all TeX submissions, all relevant editable source must be submitted during the submission 
process. Failing to submit these source files will cause unnecessary delays in the publication 
procedures. 
Publishing Datasets 
Through a special arrangement with LabArchives, LLC, authors submitting manuscripts to Journal of 
Hematology & Oncology can obtain a complimentary subscription to LabArchives with an allotment 
of 100MB of storage. LabArchives is an Electronic Laboratory Notebook which will enable scientists 
to share and publish data files in situ; you can then link your paper to these data. Data files linked to 
published articles are assigned digital object identifiers (DOIs) and will remain available in 
perpetuity. Use of LabArchives or similar data publishing services does not replace preexisting data 
deposition requirements, such as for nucleic acid sequences, protein sequences and atomic 
coordinates. 
Instructions on assigning DOIs to datasets, so they can be permanently linked to publications, can be 
found on the LabArchives website. Use of LabArchives’ software has no influence on the editorial 
decision to accept or reject a manuscript. 
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Authors linking datasets to their publications should include an Availability of supporting data 
section in their manuscript and cite the dataset in their reference list. 
Preparing main manuscript text 
General guidelines of the journal's style and language are given below. 
Overview of manuscript sections for Research Articles 
Manuscripts for Research Articles submitted to Journal of Hematology & Oncology should be divided 
into the following sections (in this order): 
 Title page
 Abstract
 Additional non-English language abstract
 Keywords
 Background
 Results and discussion
 Conclusions
 Methods







 Illustrations and figures (if any)
 Tables and captions
 Preparing additional files
The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates 
cited in the manuscript should be provided, in square brackets and include the corresponding 
database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, 
GenBank:U49845, PDB:1BFM, Swiss-Prot:Q96KQ7, PIR:S66116]. 
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The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database 
(EMBL), DNA Data Bank of Japan (DDBJ), GenBank at the NCBI (GenBank), Protein Data Bank (PDB), 
Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot). 
You can download a template (Mac and Windows compatible; Microsoft Word 98/2000) for your 
article. 
For reporting standards please see the information in the About section. 
Title page 
The title page should: 
 provide the title of the article
 list the full names, institutional addresses and email addresses for all authors
 indicate the corresponding author
Please note: 
 the title should include the study design, for example "A versus B in the treatment of C: a
randomized controlled trial X is a risk factor for Y: a case control study"
 abbreviations within the title should be avoided
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be structured into separate 
sections: Background, the context and purpose of the study; Methods, how the study was 
performed and statistical tests used; Results, the main findings; Conclusions, brief summary and 
potential implications. Please minimize the use of abbreviations and do not cite references in the 
abstract. Trial registration, if your research reports the results of a controlled health care 
intervention, please list your trial registry, along with the unique identifying number (e.g. Trial 
registration: Current Controlled Trials ISRCTN73824458). Please note that there should be no space 
between the letters and numbers of your trial registration number. We recommend manuscripts 
that report randomized controlled trials follow the CONSORT extension for abstracts. 
Additional non-English language abstract 
An additional non-English language abstract can be included within the article. The additional 
abstract should be placed after the official English language abstract in the submitted manuscript file 
and should not exceed 350 words. Please ensure you indicate the language of your abstract. In 
addition to English, we can support German, Spanish, French, Norwegian and Portuguese abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background  
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The Background section should be written in a way that is accessible to researchers without 
specialist knowledge in that area and must clearly state - and, if helpful, illustrate - the background 
to the research and its aims. Reports of clinical research should, where appropriate, include a 
summary of a search of the literature to indicate why this study was necessary and what it aimed to 
contribute to the field. The section should end with a brief statement of what is being reported in 
the article. 
Results and discussion 
The Results and discussion may be combined into a single section or presented separately. Results of 
statistical analysis should include, where appropriate, relative and absolute risks or risk reductions, 
and confidence intervals. The Results and discussion sections may also be broken into subsections 
with short, informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear explanation of their 
importance and relevance. Summary illustrations may be included. 
Methods 
The methods section should include the design of the study, the type of materials involved, a clear 
description of all comparisons, and the type of analysis used, to enable replication. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, and a list of 
abbreviations can be provided, which should precede the competing interests and authors' 
contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of information may be 
influenced by your personal or financial relationship with other people or organizations. Authors 
must disclose any financial competing interests; they should also reveal any non-financial competing 
interests that may cause them embarrassment were they to become public after the publication of 
the manuscript. 
Authors are required to complete a declaration of competing interests. All competing interests that 
are declared will be listed at the end of published articles. Where an author gives no competing 
interests, the listing will read 'The author(s) declare that they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
 In the past five years have you received reimbursements, fees, funding, or salary from an
organization that may in any way gain or lose financially from the publication of this
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manuscript, either now or in the future? Is such an organization financing this manuscript 
(including the article-processing charge)? If so, please specify. 
 Do you hold any stocks or shares in an organization that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future? If so, please
specify.
 Do you hold or are you currently applying for any patents relating to the content of the
manuscript? Have you received reimbursements, fees, funding, or salary from an
organization that holds or has applied for patents relating to the content of the manuscript?
If so, please specify.
 Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, ideological, academic, 
intellectual, commercial or any other) to declare in relation to this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing interest please discuss 
it with the editorial office. 
Authors' contributions 
In order to give appropriate credit to each author of a paper, the individual contributions of authors 
to the manuscript should be specified in this section. 
An 'author' is generally considered to be someone who has made substantive intellectual 
contributions to a published study. To qualify as an author one should 1) have made substantial 
contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 
2) have been involved in drafting the manuscript or revising it critically for important intellectual
content; and 3) have given final approval of the version to be published. Each author should have
participated sufficiently in the work to take public responsibility for appropriate portions of the
content. Acquisition of funding, collection of data, or general supervision of the research group,
alone, does not justify authorship.
We suggest the following kind of format (please use initials to refer to each author's contribution): 
AB carried out the molecular genetic studies, participated in the sequence alignment and drafted the 
manuscript. JY carried out the immunoassays. MT participated in the sequence alignment. ES 
participated in the design of the study and performed the statistical analysis. FG conceived of the 
study, and participated in its design and coordination and helped to draft the manuscript. All authors 
read and approved the final manuscript.  
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged include a person who 




You may choose to use this section to include any relevant information about the author(s) that may 
aid the reader's interpretation of the article, and understand the standpoint of the author(s). This 
may include details about the authors' qualifications, current positions they hold at institutions or 
societies, or any other relevant background information. Please refer to authors using their initials. 
Note this section should not be used to describe any competing interests. 
Acknowledgements 
Please acknowledge anyone who contributed towards the article by making substantial 
contributions to conception, design, acquisition of data, or analysis and interpretation of data, or 
who was involved in drafting the manuscript or revising it critically for important intellectual 
content, but who does not meet the criteria for authorship. Please also include the source(s) of 
funding for each author, and for the manuscript preparation. Authors must describe the role of the 
funding body, if any, in design, in the collection, analysis, and interpretation of data; in the writing of 
the manuscript; and in the decision to submit the manuscript for publication. Please also 
acknowledge anyone who contributed materials essential for the study. If a language editor has 
made significant revision of the manuscript, we recommend that you acknowledge the editor by 
name, where possible.  
The role of a scientific (medical) writer must be included in the acknowledgements section, including 
their source(s) of funding. We suggest wording such as 'We thank Jane Doe who provided medical 
writing services on behalf of XYZ Pharmaceuticals Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section. 
Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter and all notes 
(along with their corresponding letter) should be included in the Endnotes section. Please format 
this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square brackets, in the order in 
which they are cited in the text, followed by any in tables or legends. Each reference must have an 
individual reference number. Please avoid excessive referencing. If automatic numbering systems 
are used, the reference numbers must be finalized and the bibliography must be fully formatted 
before submission. 
Only articles, datasets, clinical trial registration records and abstracts that have been published or 
are in press, or are available through public e-print/preprint servers, may be cited; unpublished 
abstracts, unpublished data and personal communications should not be included in the reference 
list, but may be included in the text and referred to as "unpublished observations" or "personal 
communications" giving the names of the involved researchers. Obtaining permission to quote 
84 
personal communications and unpublished data from the cited colleagues is the responsibility of the 
author. Footnotes are not allowed, but endnotes are permitted. Journal abbreviations follow Index 
Medicus/MEDLINE. Citations in the reference list should include all named authors, up to the first 30 
before adding 'et al.'.. 
Any in press articles cited within the references and necessary for the reviewers' assessment of the 
manuscript should be made available if requested by the editorial office. 
Style files are available for use with popular bibliographic management software: 
 BibTeX
 EndNote style file
 Reference Manager
 Zotero
Examples of the Journal of Hematology & Oncology reference style are shown below. Please ensure 
that the reference style is followed precisely; if the references are not in the correct style they may 
have to be retyped and carefully proofread.  
All web links and URLs, including links to the authors' own websites, should be given a reference 
number and included in the reference list rather than within the text of the manuscript. They should 
be provided in full, including both the title of the site and the URL, in the following format: The 
Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do]. If an author or 
group of authors can clearly be associated with a web link, such as for weblogs, then they should be 
included in the reference. 
Examples of the Journal of Hematology & Oncology reference style 
Article within a journal 
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. Nat Genet 1996, 13:266-
267. 
Article within a journal supplement 
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio three-
dimensional prediction, secondary structure, and contacts prediction. Proteins 1999, 43(Suppl 
3):149-170. 
In press article 
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur Respir J, in press. 
Published abstract 
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, stromal 
derived factor-1 and rheumatoid arthritis [abstract]. Arthritis Rheum 1999, 42:s250. 
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Article within conference proceedings 
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on 
Porous Sieves: 27-30 June 1996; Baltimore. Edited by Smith Y. Stoneham: Butterworth-Heinemann; 
1996:16-27. 
Book chapter, or article within a book 
Schnepf E: From prey via endosymbiont to plastids: comparative studies in dinoflagellates. In 
Origins of Plastids. Volume 2. 2nd edition. Edited by Lewin RA. New York: Chapman and Hall; 
1993:53-76. 
Whole issue of journal 
Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-72. 
Whole conference proceedings 
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; 
Baltimore. Stoneham: Butterworth-Heinemann; 1996. 
Complete book 
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970. 
Monograph or book in a series 
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited 
by Harris TJR. New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): Methods and 
Perspectives in Cell Biology, vol 1.] 
Book with institutional author 
Advisory Committee on Genetic Modification: Annual Report. London; 1999. 
PhD thesis 
Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. 
Stanford University, Computer Science Department; 1995. 
Link / URL 
The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/mtbwi/index.do] 
Link / URL with author(s) 
Corpas M: The Crowdfunding Genome Project: a personal genomics community with open source 
values [http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-crowdfunding-genome-project-a-
personal-genomics-community-with-open-source-values/]  
Dataset with persistent identifier 
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, T-F; Jiang, S; Ramachandran, S; Liu, C-M; 
Jing, H-C (2011): Genome data from sweet and grain sorghum (Sorghum bicolor). GigaScience. 
http://dx.doi.org/10.5524/100012. 
Clinical trial registration record with persistent identifier 
Mendelow, AD (2006): Surgical Trial in Lobar Intracerebral Haemorrhage. Current Controlled Trials. 
http://dx.doi.org/10.1186/ISRCTN22153967 
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Preparing illustrations and figures 
Illustrations should be provided as separate files, not embedded in the text file. Each figure should 
include a single illustration and should fit on a single page in portrait format. If a figure consists of 
separate parts, it is important that a single composite illustration file be submitted which contains all 
parts of the figure. There is no charge for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on maximising the quality of 
your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams)
 DOCX/DOC (single page only)
 PPTX/PPT (single slide only)
 EPS





The legends should be included in the main manuscript text file at the end of the document, rather 
than being a part of the figure file. For each figure, the following information should be provided: 
Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title of figure 
(maximum 15 words); detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from the copyright 
holder to reproduce figures or tables that have previously been published elsewhere. 
Preparing a personal cover page 
If you wish to do so, you may submit an image which, in the event of publication, will be used to 
create a cover page for the PDF version of your article. The cover page will also display the journal 
logo, article title and citation details. The image may either be a figure from your manuscript or 
another relevant image. You must have permission from the copyright to reproduce the image. 
Images that do not meet our requirements will not be used. 
Images must be 300dpi and 155mm square (1831 x 1831 pixels for a raster image). 
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Allowable formats - EPS, PDF (for line drawings), PNG, TIFF (for photographs and screen dumps), 
JPEG, BMP, DOC, PPT, CDX, TGF (ISIS/Draw). 
Preparing tables 
Each table should be numbered and cited in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). 
Tables should also have a title (above the table) that summarizes the whole table; it should be no 
longer than 15 words. Detailed legends may then follow, but they should be concise. Tables should 
always be cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the end of the 
document text file, in A4 portrait or landscape format. These will be typeset and displayed in the 
final published form of the article. Such tables should be formatted using the 'Table object' in a word 
processing program to ensure that columns of data are kept aligned when the file is sent 
electronically for review; this will not always be the case if columns are generated by simply using 
tabs to separate text. Columns and rows of data should be made visibly distinct by ensuring that the 
borders of each cell display as black lines. Commas should not be used to indicate numerical values. 
Color and shading may not be used; parts of the table can be highlighted using symbols or bold text, 
the meaning of which should be explained in a table legend. Tables should not be embedded as 
figures or spreadsheet files. 
Larger datasets or tables too wide for a landscape page can be uploaded separately as additional 
files. Additional files will not be displayed in the final, laid-out PDF of the article, but a link will be 
provided to the files as supplied by the author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls ) or comma 
separated values (.csv). As with all files, please use the standard file extensions. 
Preparing additional files 
Although Journal of Hematology & Oncology does not restrict the length and quantity of data 
included in an article, we encourage authors to provide datasets, tables, movies, or other 
information as additional files. 
Please note: All Additional files will be published along with the article. Do not include files such as 
patient consent forms, certificates of language editing, or revised versions of the main manuscript 
document with tracked changes. Such files should be sent by email to editor@jhoonline.org, quoting 
the Manuscript ID number. 
Results that would otherwise be indicated as "data not shown" can and should be included as 
additional files. Since many weblinks and URLs rapidly become broken, Journal of Hematology & 
Oncology requires that supporting data are included as additional files, or deposited in a recognized 
repository. Please do not link to data on a personal/departmental website. The maximum file size for 
additional files is 20 MB each, and files will be virus-scanned on submission.  
Additional files can be in any format, and will be downloadable from the final published article as 
supplied by the author. We recommend CSV rather than PDF for tabular data. 
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Certain supported files formats are recognized and can be displayed to the user in the browser. 
These include most movie formats (for users with the Quicktime plugin), mini-websites prepared 
according to our guidelines, chemical structure files (MOL, PDB), geographic data files (KML).  
If additional material is provided, please list the following information in a separate section of the 
manuscript text: 
 File name (e.g. Additional file 1)
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx (including
name and a URL of an appropriate viewer if format is unusual)
 Title of data
 Description of data
Additional files should be named "Additional file 1" and so on and should be referenced explicitly by 
file name within the body of the article, e.g. 'An additional movie file shows this in more detail [see 
Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should be viewable using 
free or widely available tools. The following are examples of suitable formats. 
 Additional documentation
o PDF (Adode Acrobat)
 Animations
o SWF (Shockwave Flash)
 Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
 Tabular data
o XLS, XLSX (Excel Spreadsheet)
o CSV (Comma separated values)
As with figure files, files should be given the standard file extensions. 
Mini-websites 
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Small self-contained websites can be submitted as additional files, in such a way that they will be 
browsable from within the full text HTML version of the article. In order to do this, please follow 
these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in the root.
2. Put all files necessary for viewing the mini-website within the folder, or sub-folders.
3. Ensure that all links are relative (ie "images/picture.jpg" rather than "/images/picture.jpg" or
"http://yourdomain.net/images/picture.jpg" or "C:\Documents and Settings\username\My
Documents\mini-website\images\picture.jpg") and no link is longer than 255 characters.
4. Access the index.html file and browse around the mini-website, to ensure that the most
commonly used browsers (Internet Explorer and Firefox) are able to view all parts of the
mini-website without problems, it is ideal to check this on a different machine.
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure that index.html is
in the root of the ZIP, and that the file has .zip extension, then submit as an additional file
with your article.
Style and language 
General 
Currently, Journal of Hematology & Oncology can only accept manuscripts written in English. 
Spelling should be US English or British English, but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are encouraged to be 
concise.  
Journal of Hematology & Oncology will not edit submitted manuscripts for style or language; 
reviewers may advise rejection of a manuscript if it is compromised by grammatical errors. Authors 
are advised to write clearly and simply, and to have their article checked by colleagues before 
submission. In-house copyediting will be minimal. Non-native speakers of English may choose to 
make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, please visit our page 
on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific manuscript. 
American Scientist also provides a list of resources for science writing. For more detailed guidance 
on preparing a manuscript and writing in English, please visit the BioMed Central author academy. 
Abbreviations 
Abbreviations should be used as sparingly as possible. They should be defined when first used and a 
list of abbreviations can be provided following the main manuscript text. 
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Typography 
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
 Use hard returns only to end headings and paragraphs, not to rearrange lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the Journal of Hematology & Oncology reference format.
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are unable to reproduce a
particular special character, please type out the name of the symbol in full. Please ensure
that all special characters used are embedded in the text, otherwise they will be lost
during conversion to PDF.
Units 
SI units should be used throughout (liter and molar are permitted, however). 
